TW200608959A - Treatment with oxaliplatin and an egfr-inhibitor - Google Patents
Treatment with oxaliplatin and an egfr-inhibitorInfo
- Publication number
- TW200608959A TW200608959A TW094118061A TW94118061A TW200608959A TW 200608959 A TW200608959 A TW 200608959A TW 094118061 A TW094118061 A TW 094118061A TW 94118061 A TW94118061 A TW 94118061A TW 200608959 A TW200608959 A TW 200608959A
- Authority
- TW
- Taiwan
- Prior art keywords
- kinase inhibitor
- oxaliplatin
- egfr kinase
- combination
- egfr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57643504P | 2004-06-03 | 2004-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200608959A true TW200608959A (en) | 2006-03-16 |
Family
ID=34970379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094118061A TW200608959A (en) | 2004-06-03 | 2005-06-01 | Treatment with oxaliplatin and an egfr-inhibitor |
Country Status (17)
Country | Link |
---|---|
US (1) | US20050272738A1 (zh) |
EP (1) | EP1755622A1 (zh) |
JP (1) | JP2008501650A (zh) |
KR (1) | KR100881043B1 (zh) |
CN (1) | CN1960737A (zh) |
AR (1) | AR049135A1 (zh) |
AU (1) | AU2005249200A1 (zh) |
BR (1) | BRPI0511780A (zh) |
CA (1) | CA2566974A1 (zh) |
IL (1) | IL179367A0 (zh) |
MX (1) | MXPA06013997A (zh) |
NO (1) | NO20066057L (zh) |
NZ (1) | NZ551354A (zh) |
RU (1) | RU2006146623A (zh) |
TW (1) | TW200608959A (zh) |
WO (1) | WO2005117915A1 (zh) |
ZA (1) | ZA200610050B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005117877A1 (en) * | 2004-06-03 | 2005-12-15 | F.Hoffmann-La Roche Ag | Treatment with irinotecan (cpt-11) and an egfr-inhibitor |
WO2006081985A1 (en) * | 2005-02-04 | 2006-08-10 | F. Hoffmann-La Roche Ag | Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor |
UA98665C2 (ru) * | 2010-03-25 | 2012-06-11 | Геннадий Васильевич Мазильников | Лекарственный препарат, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения |
UA98666C2 (ru) * | 2010-03-25 | 2012-06-11 | Геннадий Васильевич Мазильников | Лекарственный препарат на основе щавелевой кислоты, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения |
MX2013006361A (es) * | 2010-12-09 | 2013-07-30 | Hoffmann La Roche | Agtr1 como marcador para terapias combinadas de bevacizumab. |
AU2013308464B2 (en) * | 2012-08-31 | 2018-02-01 | Taris Biomedical Llc | Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin |
US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL146480A0 (en) * | 1999-05-14 | 2002-07-25 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
JP2003502025A (ja) * | 1999-05-17 | 2003-01-21 | エイブイアイ バイオファーマ, インコーポレイテッド | hcGワクチンを用いた癌の処置のための併用アプローチ |
US7049059B2 (en) * | 2000-12-01 | 2006-05-23 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression |
AU2002219221B2 (en) * | 2001-01-09 | 2007-05-17 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
AU2004266572A1 (en) * | 2003-08-01 | 2005-03-03 | Wyeth Holdings Corporation | Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
WO2005060951A2 (en) * | 2003-12-19 | 2005-07-07 | Bionaut Pharmaceuticals, Inc. | Anti-neoplastic agents, combination therapies and related methods |
-
2005
- 2005-05-25 MX MXPA06013997A patent/MXPA06013997A/es not_active Application Discontinuation
- 2005-05-25 KR KR1020067025439A patent/KR100881043B1/ko not_active IP Right Cessation
- 2005-05-25 CN CNA2005800179701A patent/CN1960737A/zh active Pending
- 2005-05-25 CA CA002566974A patent/CA2566974A1/en not_active Abandoned
- 2005-05-25 JP JP2007513799A patent/JP2008501650A/ja active Pending
- 2005-05-25 AU AU2005249200A patent/AU2005249200A1/en not_active Abandoned
- 2005-05-25 RU RU2006146623/15A patent/RU2006146623A/ru unknown
- 2005-05-25 WO PCT/EP2005/005638 patent/WO2005117915A1/en active Application Filing
- 2005-05-25 BR BRPI0511780-1A patent/BRPI0511780A/pt not_active IP Right Cessation
- 2005-05-25 EP EP05751864A patent/EP1755622A1/en not_active Withdrawn
- 2005-05-25 NZ NZ551354A patent/NZ551354A/en unknown
- 2005-06-01 AR ARP050102243A patent/AR049135A1/es not_active Application Discontinuation
- 2005-06-01 TW TW094118061A patent/TW200608959A/zh unknown
- 2005-06-03 US US11/145,091 patent/US20050272738A1/en not_active Abandoned
-
2006
- 2006-11-16 IL IL179367A patent/IL179367A0/en unknown
- 2006-11-30 ZA ZA200610050A patent/ZA200610050B/xx unknown
- 2006-12-28 NO NO20066057A patent/NO20066057L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR049135A1 (es) | 2006-06-28 |
NO20066057L (no) | 2007-02-28 |
JP2008501650A (ja) | 2008-01-24 |
NZ551354A (en) | 2009-10-30 |
WO2005117915A1 (en) | 2005-12-15 |
IL179367A0 (en) | 2007-03-08 |
CN1960737A (zh) | 2007-05-09 |
BRPI0511780A (pt) | 2008-01-15 |
CA2566974A1 (en) | 2005-12-15 |
ZA200610050B (en) | 2008-08-27 |
EP1755622A1 (en) | 2007-02-28 |
US20050272738A1 (en) | 2005-12-08 |
RU2006146623A (ru) | 2008-07-20 |
MXPA06013997A (es) | 2007-02-08 |
AU2005249200A1 (en) | 2005-12-15 |
KR20070029185A (ko) | 2007-03-13 |
KR100881043B1 (ko) | 2009-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007004549A (es) | Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico. | |
TW200603804A (en) | Treatment with irinotecan (cpt-11) and an EGFR-inhibitor | |
WO2007106503A3 (en) | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors | |
WO2006110176A3 (en) | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor | |
NO20066056L (no) | Behandling med Gemcitabin og en EGFR-inhibitor | |
WO2007075554A3 (en) | Combination of igfr inhibitor and anti-cancer agent | |
NO20066054L (no) | behandling med cisplatin og en EGFR-inhibitor | |
MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
MX2007009960A (es) | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. | |
WO2009008992A3 (en) | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 | |
EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
TW200608959A (en) | Treatment with oxaliplatin and an egfr-inhibitor | |
EA201000127A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
BR0207443A (pt) | Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina | |
RU2008148597A (ru) | Фармацевтические комбинации | |
WO2009073139A3 (en) | Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit | |
CA2514227A1 (en) | Combination therapy of zd6474 with 5-fu or/and cpt-11 | |
EA200501166A1 (ru) | Составы и способы лечения тромбоцитемии | |
WO2011094260A3 (en) | Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer | |
CA2531620A1 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
MXPA04009012A (es) | Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer. | |
MXPA05004920A (es) | Combinacion que comprende un inhibidor cdk y cisplatin. | |
MXPA05013827A (es) | Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g. | |
MX2023005695A (es) | Administracion de agonista de sting, inhibidores de puntos de control y radiacion. |